AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer by Vandana Singh Benzinga Editor Follow ...

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

WILMINGTON, Del. -- (BUSINESS WIRE)-- AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Based on these impressive data from the AMPLIFY trial, CALQUENCE is the only second-generation BTK inhibitor to ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “ These impactful results in mantle cell lymphoma show that bringing CALQUENCE to the first-line setting significantly ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced positive high-level results from an interim analysis of the AMPLIFY Phase III trial, showing that a fixed duration of the company's Calquence ...

AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S. Jan. 17, 2025 9:36 AM ET AstraZeneca PLC (AZN) Stock By: Dulan Lokuwithana, SA News Editor Play (1min) ...

AstraZeneca Plc <AZN.L> said on Tuesday it would start a clinical trial of its cancer drug Calquence to assess its potential to control the exaggerated immune system response associated with ...